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Griseofulvin (GF) and terbinafine (TF) are commonly used drugs to treat dermatophytosis, a fungal 
infection of the skin. Today there is an increase in drug resistance to these antifungals which highlight 
the need for alternative synergistic therapies. Minimum Inhibitory Concentration (MIC) of GF and TF 
were determined against fungi clinical isolates from local hospitals with values ranging 0.03−2.0 µg 
mL-1 and 0.24−4.0 µg mL-1, respectively. A checkboard test was used to determine the combination 
of GF:TF which could induce an additive effect against the fungi isolates Multidrug-resistant isolates 
showed susceptibility after treatment with 16:2 µg mL-1 GF:TF. An MTT assay further verified that GF 
and TF combinations have greater additive effect against pathological and multidrug-resistant isolates 
than antifungals alone. Herein we disclose GF:TF combinations that could constitute as a possible new 
anti-dermatophyte therapy. 
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INTRODUCTION
Skin infections caused by dermatophytes fungus are 
common and widespread worldwide. The disease causing 
fungus result primarily from three genus Epidermophyton, 
Microsporum, and Trichophyton. These infections are 
typically limited to the stratum corneum of skin, nails, 
and scalp, causing tinea-like mycoses and onychomycosis 
characterized by the symptoms of local irritation, scaling, 
redness, swelling, and inflammation (Patel, Schwartz, 
2011). Although rarely fatal, these fungal diseases are 
considered difficult to treat, since their therapy is long and 
frequently recur (Molina de Diego, 2011).
Fungal resistance to conventional antifungals is on 
the rise which further complicates the treatment (Grover, 
Arora, Manchanda, 2012). In addition, it is especially 
difficult to treat immunocompromised patients because 
of high toxicity associated with many antifungal agents 
(Vandeputte, Ferrari, Coste, 2012). Griseofulvin (GF) 
and terbinafine (TF) are among the most commonly used 
drugs for the treatment of dermatophytosis but often not 
effective alone (Badali et al., 2015).
The current approach to treat dermatophytosis 
utilizes a combination of antifungals to overcome 
fungal resistance, especially in chronic cases (Tamura 
et al., 2014). This strategy has been successful against 
other diseases and is particularly attractive to the 
pharmaceutical industry since approved drugs gain extra 
lifetime. 
GF and TF act on different targets in the fungal cell. 
GF alters DNA synthesis inhibiting mitosis by interfering 
with microtubules function (Kathiravan et al., 2012). 
Whereas, TF inhibits squalene epoxidase leading to 
ergosterol depletion and squalene accumulation (Campoy 
et al., 2017; Scorzoni et al., 2017). 
Co-administration of drugs of different mechanisms 
of action can often be synergist through inhibition of 
complementary targets inside fungal cells (Scorzoni et al., 
2017). This strategy has been shown to achieve a wider 
spectrum of antifungal activity (Mukherjee et al., 2005; 
Campitielli et al., 2017; Scorzoni et al., 2017).
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Herein, we present a study of the in vitro effects of 
GF and TF combinations against multidrug-resistant fungi 
using fungi clinical isolates, which are simultaneously or 
individually resistant to GF and TF.
MATERIAL AND METHODS
Microorganisms
Cl in ica l  fung i  i so la tes  ( t en  s t r a ins  o f  T. 
mentagrophytes, eleven of T. rubrum, eight of M. 
canis, and twelve of M. gypseum) were obtained from 
the culture collections deposited on the Laboratory of 
Applied Mycological Research, Universidade Federal do 
Rio Grande do Sul, Brazil. PCR and direct sequencing, 
targeting the internal transcribed spacer (ITS) region of 
rDNA, were used in the identification of T. mentagrophytes 
isolates employed in this study.
Antifungal solutions
Stock solutions of GF (Wallace Pharmaceuticals, 
Mumbai, India) and TF (terbinafine hydrochloride - 
Cristália, São Paulo, Brazil) were prepared by dilution 
with dimethyl sulfoxide (DMSO; Synth, São Paulo) at 
1600 µg mL-1 and stored at −20 °C. For the experiments, 
antifungal drugs were diluted with RPMI 1640 (Roswell 
Park Memorial Institute; Gibco) medium supplemented 
with L-glutamine, without sodium bicarbonate, and 
buffered at pH 7.0 with MOPS (morpholinepropansulfonic 
acid; Sigma-Aldrich) buffer 0.165 M. After dilution, the 
maximum final concentration of DMSO was 2%.
Antifungal susceptibility testing
The minimum inhibitory concentration (MIC) 
of each antifungal drug was determined by the broth 
microdilution method using RPMI 1640 medium, 
according to CLSI protocol M38-A2 (CLSI, 2008). GF and 
TF resistance was defined as MIC ≥ 3 µg mL-1 (Galuppi et 
al., 2010) and MIC ≥ 4 µg mL-1 (Mukherjee et al., 2003), 
respectively, since no breakpoints are available in the CLSI 
and EUCAST for these drugs. Sterility (without drugs and 
fungi) and cell viability controls were used respectively 
and performed in triplicate.
Phenotypic Study of ATP-binding cassette (ABC) 
efflux pumps
MICs of GF and TF were determined to the multi-
resistant isolates in the presence of verapamil (100 µM, 
RPMI) into the culture medium and compared with the 
MIC values without the addition of this efflux pump 
inhibitor (Pinto e Silva et al., 2009). Incubation conditions 
were the same as those used on antifungal susceptibility 
tests.
Susceptibility assay of the combined antifungal 
drugs by the checkerboard method
Two-dimensional  charac ter iza t ion  of  the 
GF:TF interaction was performed in quadruplicate 
by checkerboard technique as previously described 
by Lewis et al. (2002). Antifungal interactions were 
evaluated by comparing the fractional inhibitory 
concentration index (FICI) expressed as the sum of the 
fractional inhibitory concentrations (FIC), as defined by 
the following equation: 
where MICGF and MICTF are the MICs of GF and TF, 
respectively (Mukherjee et al, 2005). Interactions were 
defined as synergistic (FICI ≤ 0.5), additive (0.5< FICI < 
1), indifferent (1 ≤ FICI < 4), or antagonistic (FICI ≥ 4) 
(Lewis et al., 2002).
Cell injury test of the combined antifungal drugs
After the Checkerboard time incubation, the hypha 
damage caused by GF:TF association was assayed by 
the colorimetric test using 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-
Aldrich) (Chiou et al., 2001). The supernatant from each 
microplate-well was substituted with 160 µL of MTT 
(0.05 mg mL-1 – RPMI), followed by incubation at 35 
°C for 24h. Next, the supernatant was replaced with 
200 µl of isopropanol. Then, 100 µl from each well was 
transferred to another 96-well microplate for absorbance 
(A) readings at 570 and 690 nm (EnVision 2104 Multilabel 
Reader, PerkinElmer, USA). The cell damage (CD%) was 
calculated by the equation CD% = [1 - (A570nm − A690 nm with 
drug) / (A570nm − A690 nm without drug)]×100. 
Statistical analysis
The statistical analysis was performed by ANOVA 
followed by Tukey’s test (Minitab 14.0 software, USA). 
Data expressed as mean ± SEM (Standard Error of Mean). 
Differences were considered statistically significant when 
p<0.05.
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RESULTS 
Antifungal susceptibility test
MIC and MIC50 values (Table I) showed that all 
forty-one isolates tested were more susceptible to TF than 
GF. GF MIC values among susceptible isolates varied 
from 0.25 to 2 µg mL-1. Seven isolates (MCA 36, MCA 
40, MGY 58, TME 16, TME 34, TRU 25, and TRU 43) 
were classified as resistant (MIC ≥ 3 µg mL-1) to GF. 
TF MIC results among susceptible isolates varied from 
0.03 to 2.0 µg mL-1. Two isolates (TME 16 and TME 34) 
were classified as resistant (MIC ≥ 4 µg mL-1). Finally, 
two isolates (TME 16 and TME 34) were identified as 
multi-resistant to GF and TF. Statistical analysis also 
demonstrated higher presence of GF-resistant than TF-
resistant (p<0.05) dermatophytes. 
Antifungal activity of the GF:TF combination
Seven isolates characterized as resistant to either GF 
or TF, and sixteen isolates susceptible to both antifungals 
were selected for this study. The FICI values calculated 
revealed an additive effect in about 70% of these selected 
strains (Table II). Multidrug-resistant isolates TME 16 
and TME 34 showed to be more susceptible to GF:TF 
mixtures (Table II - bold) which was unexpected but an 
encouraging result. 
Cell damage evaluation by the MTT test
Sixteen isolates, which presented additive effect 
in the qualitative checkerboard test (Table II) were then 
selected to have their its interaction substantiated by the 
quantitative MTT test The MTT test corroborates to the 
results obtained by the checkerboard assay because the GF 
and TF mixtures in all cases could inhibit greater amount 
of cell growth compared to both drugs alone. (Table III). 
The statistical analysis of cell damage verified that the 
combinations were significantly (p<0.05) more effective 
in all isolates tested. 
Cell viability was evaluated in the multidrug-
resistant isolate TME 16 (Figure 1 - A) and the drug 
sensitive isolate TME 32 (Figure 1 - B) by the MTT assay. 
It was found that cell damage to TME 16 was decreased 
by 40% after treatment with GF (32 and 16 µg mL-1) and 
TF (2 µg mL-1). In contrast, treatment with the GF:TF 
mixtures (16:2 and 64:2 µg mL-1, respectively) resulted 
in much greater cell damage (>90%) indicating possible 
hypha death due to synergy (Figure 1 – A). Similar trend 
in potency improvement was noted with to isolate TME 32 
as cell damage could be enhanced to 80% or greater after 
treatment with GF:TF mixtures (Figure 1 – B).
Statistical analysis of the cell damage further 
validate that the GF:TF combinations were significantly 
more effective in all isolates tested (p<0.05).
Phenotypic study of ABC efflux pumps
Effect of ABC efflux-pumps on potency was checked 
by using Verapamil (Sigma), a known efflux pump 
inhibitor. Drug efflux is one of the main mechanisms 
responsible for decrease the MIC within drug resistant 
organism. It was found that the MICs of GF and TF were 
not changed with addition of verapamil suggesting that 
drug efflux is not responsible for drug resistance.
DISCUSSION
According to the critical points chosen from Table I, 
seven out forty-one isolates assayed were classified as 
resistant to GF (MIC values ≥ 3 µg mL-1) (Galuppi et al., 
2010). This finding is consistent with previously reported 
results (Galuppi et al., 2010; Nardoni et al., 2013) as was 
the prevalence of GF-resistant isolates compared to TF 
(Andes et al., 2006).
Two T. mentagrophytes isolates (TME 16 and TME 
32) showed resistance to GF and TF. This resistance to 
distinct antifungal drug classes is alarming, since the 
probability of therapeutic-treatment failure could be 
extremely high when these agents are given alone. The 
multi-drug resistance of dermatophytes to GF and TF is 
unusual, so further tests was performed focusing on these 
two multidrug-resistant isolates.
Literature has reported that one particular fungi 
strain (having resistance to GF, and tioconazole) which 
was related to the efflux pumps (Fachin, Maffei, Martinez-
Rossi, 1996). Therefore, we hypothesized that TME 16 
and TME 32 might be drug resistant due to the activity of 
efflux pumps. This was checked using verapamil to inhibit 
the ABC efflux pumps and MICs determined. Since the 
MICs were not improved upon addition of verapamil it 
is suggestive that the mechanism of resistance is not drug 
efflux. Additional studies will need to be conducted to 
further verify this result and uncover the mechanism of 
drug resistance. 
Dermatophytosis is often a chronic, recurrent 
disease which can require long-term treatment with 
antifungals. Therefore, it is important to choose the 
most appropriate and effective drugs in the early stages 
of infection. Combination therapy of antifungals with 
different pharmacological effects has shown to have 
A. J. D. Lana, B. Pippi, A. R. Carvalho, R. C. Moraes, S. Kaiser, G. G. Ortega, A. M. Fuentefria, G. P. Silveira
Braz. J. Pharm. Sci. 2018;54(2):e17149Page 4 / 9
TABLE I - MICs to GF and TF against dermatophyte isolates 
Isolates
GF (µg/mL) TF (µg/mL)
MIC Mean MIC MIC50 MIC Mean MIC MIC50
Microsporum canis
MCA 01 1.0
8.38 0.5
0.03
0.30 0.125
MCA 29 0.5 0.125
MCA 32 0.5 0.125
MCA 36 >32.0 1.0
MCA W3 0.25 0.06
MCA 38 0.5 0.03
MCA 39 0.25 0.03
MCA 40 >32.0 1.0
Microsporum gypseum
MGY 42 1.0
3.91 1.0
0.03
0.24 0.06
MGY 45 1.0 0.03
MGY 46 1.0 0.03
MGY 48 2.0 0.125
MGY 49 1.0 0.03
MGY 50 2.0 0.125
MGY 51 2.0 0.25
MGY 52 1.0 0.125
MGY 53 2.0 0.06
MGY 54 1.0 0.06
MGY 57 1.0 0.03
MGY 58 >32.0 2.0
Trichophyton mentagrophytes
TME 16 >32.0
7.15 0.5
4.0
0.84 0.03
TME 18 2.0 0.06
TME 31 0.5 0.03
TME 32 1.0 0.06
TME 33 0.5 0.03
TME 34 >32.0 4.0
TME 38 2.0 0.03
TME 40 0.5 0.03
TME 44 0.5 0.03
TME 46 0.5 0.125
Trichophyton rubrum
TRU 20 1.0
4.45 1.0
0.06
0.12 0.03
TRU 23 1.0 0.03
TRU 25 >32.0 1.0
TRU 40 1.0 0.06
TRU 42 2.0 0.03
TRU 43 4.0 0.03
TRU 46 2.0 0.03
TRU 48 2.0 0.03
TRU 49 1.0 0.03
TRU 50 1.0 0.06
TRU 52 2.0 0.03
Isolates having MIC ≥ 4 µg/ml are classified as resistant to the drugs. Bold: multi-resistant isolates.
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TABLE II - Fractional inhibitory concentration index (FICI) and type of interaction obtained for hyphae by testing GF:TF 
combinations according to the checkerboard microdilution method (qualitative methodology)
Isolates
MIC (µg/mL) MIC Combinations (µg/mL)
FICI Interaction
GF TF GF TF
MCA 29 0.50 0.12 0.25 0.06 0.98 Add
MCA 32 0.50 0.12 0.25 0.06 0.98 Add
MCA 36 32.00 1.00 0.25 1.00 1.01 Ind
MCA 38 0.50 0.03 0.12 0.01 0.58 Add
MCA 39 0.25 0.03 0.06 0.01 0.57 Add
MCA 40 32.00 1.00 0.25 1.00 1.01 Ind
MGY 46 2.00 0.03 0.50 0.01 0.58 Add
MGY 48 2.00 0.12 0.12 0.06 0.54 Add
MGY 50 2.00 0.12 0.50 0.06 0.73 Add
MGY 53 2.00 0.06 0.50 0.03 0.75 Add
MGY 58 32.00 2.00 0.25 2.00 1.01 Ind
TME 16* 64.00 4.00 16.00 2.00 0.75 Add
TME 18 2.00 0.06 1.00 0.06 0.67 Add
TME 32 1.00 0.06 0.06 0.03 0.56 Add
TME 33 0.50 0.03 0.03 0.03 1.06 Ind
TME 34* 64.00 4.00 16.00 2.00 0.75 Add
TRU 20 1.00 0.06 0.125 0.03 0.63 Add
TRU 25 32.00 1.00 0.25 1.00 1.01 Ind
TRU 42 2.00 0.03 1.00 0.007 0.73 Add
TRU 46 2.00 0.06 0.50 0.03 0.75 Add
TRU 48 2.00 0.03 0.25 0.03 1.01 Ind
TRU 50 1.00 0.06 0.50 0.03 1.00 Ind
TRU 52 2.00 0.06 0.25 0.03 0.63 Add
Synergistic (Syn); additive (Add); indifferent (Ind). *multi-resistant isolates.
TABLE III - Cell damage after treatment with GF, TF, and GF:TF combinations (quantitative methodology)
Strains
C (µg/mL) GF, TF 
CDA (%) GF, TF  
CDC (%) GF:TF Combinations
Comb 1 Comb 2 Comb 3
MCA 29
C 0.25 0.06
CDA 27.9% C 42.7 B
CDC 80.9 A
MCA 32
C 0.25 0.06
CDA 62.6% B 51.2 C
CDC 87.3 A
MCA 38
C 0.25 0.01 0.125 0.01 0.25 0.007
CDA 55.3% B 63.1 B 37.2% C 63.1 B 55.3% B 39.3 C
CDC 89.6 A 88.7 A 88.0 A
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Strains
C (µg/mL) GF, TF 
CDA (%) GF, TF  
CDC (%) GF:TF Combinations
Comb 1 Comb 2 Comb 3
MCA39
C 0.25 0.01 0.125 0.01
CDA 36.2% B 37.1 B 35.2% B 37.1 B
CDC 82.6 A 80.5 A
MGY 46
C 1.0 0.125 0.125 0.5
CDA 20.7% D 36.3 C 36.3 C 11.4% E
CDC 87.7 A 80.2 A
MGY 48
C 1.0 0.06 0.25 0.06 0.125 0.06
CDA 64.9% B 70.9 B 21.1% D 70.9 B 29.9% CD 70.9 B
CDC 91.7 A 90.3 A 88.9 A
MGY 50
C 0.5 0.06 0.06 0.25
CDA 57.9% B 53.2 B 53.2 B 34.8% C
CDC 90.1 A 82.5 A
MGY 53
C 1.0 0.03 0.5 0.03
CDA 52.8% C 27.0 D 3.9% E 27.0 D
CDC 92.7 A 80.9 B
TME 16
C 32.0 2.0 16.0 2.0
CDA 35.1% A 30.9 B 6.8% A 30.9 B
CDC 94.2 C 90.3 C
TME 18
C 1.0 0.06 1.0 0.03
CDA 67.6% C 63.5 C 67.6% C 41.1 D
CDC 90.1 A 81.7 B
TME 32
C 0.25 0.03 0.125 0.03 0.06 0.03
CDA 45.4% B 30.5 C 37.9% BC 30.5 C 31.5% C 30.5 C
CDC 83.8 A 81.6 A 80.6 A
TME 34
C 32.0 2.0 16.0 2.0
CDA 48.7% B 35.5 B 47.7% B 35.5 B
CDC 82.9 A 81.4 A
TRU 20
C 0.5 0.03 0.25 0.03 0.125 0.03
CDA 77.7% BC 67.5 C 23.5% D 67.5 C 3.9% E 67.5 C
CDC 90.5 A 93.7 A 83.1 AB
TRU 42
C 1.0 0.015 1.0 0.007
CDA 55.1% C 52.5 C 55.1% C 21.4 D
CDC 87.1 A 81.4 B
TRU 46
C 1.0 0.03 0.5 0.03
CDA 55.4% B 41.5 B 37.6% B 41.5 B
CDC 81.2 A 80.6 A
TRU 52
C 1.0 0.03 0.5 0.03 0.25 0.03
CDA 79.5% B 79.1 B 33.4% DE 79.1 B 26.6% E 79.1 B
CDC 90.7 A 91.4 A 90.8 A
Microsporum canis (MCA); Microsporum gypseum (MGY); Trichophyton mentagrophytes (TME); Trichophyton rubrum (TRU). 
C: concentration to each antifungal.CDA: percentage of cell damage to GF or TF. CDC: percentage of cell damage to GF:TF 
combinations (Ccomb=[GF]+[TF]).  Comb 1-3: concentrations of GF:TF combinations to result in cellular damage over 80%. Bold: 
indication of synergist effect. Two superscript  letters represents significance p <0.05 between treatments. One letter relates to no 
significant difference.
TABLE III - Cell damage after treatment with GF, TF, and GF:TF combinations (quantitative methodology) (cont.)
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merit for treatment of dermatophytosis (Scorzoni et al., 
2017). 
TF combined with amorolfine was checked in a 
randomized study of severe dermatophyte onychomycosis. 
Patients outcome were good and this combination 
treatment demonstrated an improvement cost per cure 
ratio (Baran et al., 2000). Onychomycosis caused 
by dermatophytes were also successfully treated by 
combination of oral terbinafine with ciclopyroxolamine, 
imidazole and other such topical antifungals. (Romano 
et al., 2005). Fusarium oxysporum infections respond 
positively to TF and topical imidazole treatment and this 
combination led to clinical and mycological healing, 
which is often refractory to antimycotics (Romano et 
al., 2005). Patient recovery to dermatophytosis was 
also achieved when GF plus cyclopyroxolamine lotion 
and GF with topical imidazole were chosen and used in 
combination therapy (Romano et al., 2005). Several other 
studies of combination therapy were reported, however 
most of these studies were lacking quantitative data 
regarding drug combinations in vitro (Spader et al., 2013; 
Semis et al., 2015).
The qualitative checkerboard assay enabled us to 
identify combinations of GF and TF which resulted in 
additive drug effects against sixteen pathogenic fungi 
(Table II). Subsequent evaluation by the quantitative 
MTT test using the same sixteen isolates identified by the 
checkerboard assay was performed and resulted in the 
determination of GF:TF concentrations that caused over 
80% of cellular damage (Figure 1).
Of great importance was discovery of GF:TF drug 
combination that could cause 90% and 80% cellular 
damage to multidrug-resistant isolates TME 16 and TME 
32, respectively.
It is possible that additive effect was achieved 
based upon the mechanism of action of GF (nucleic 
acid inhibitor) and TF (ergosterol synthesis inhibitor). 
Alteration of the membrane integrity can be linked 
to squalene epoxidase inhibition by TF, which would 
promote cellular internalization of GF; while intracellular 
accumulation would decreases DNA synthesis (Favre, 
Ryder, 1997; Polak, 1993). 
While this is only one biochemical hypothesis, it 
is also possible that intermolecular bonds in between GF 
and TB molecules could be responsible for additive effect 
observed. Our group will be pursuing additional studies 
to identify these possible interactions and the results will 
be reported in the due course.
As reported previously we found that GF has low 
solubility in water (Kahsav et al., 2013). In fact, it was 
noted that GF partially precipitates in aqueous solution 
at 35 °C. Consequently, it was necessary to mediate 
drug precipitation during incubation to avoid misleading 
results. This was first attempted by using MOPS as a buffer 
to impart enhanced compound solubility. 
However, it is not possible to make the desired stock 
solutions of GF in concentrations higher than 10 µg mL-1 
in MOPS buffer at 35 °C described at the CLSI for MIC 
determinations (CLSI, 2008). As an alternative, we found 
that we could make stock solution 1.6 mg mL-1 of GF in 
DMSO and dilution were made with RPMI 1640 media 
thereby allowing for proper MICs determinations.
In conclusion, herein we report the first investigation 
of GF and TF combination drug assessments against a 
panel of fungi clinical isolates. While, these two drugs 
have been evaluated with other antifungals (Baran et 
al., 2000; Romano et al., 2005) our findings are new and 
noteworthy particularly when pathological dermatophytes 
have become drug resistant to many antifungal drugs 
(including GF and TB alone). Through a checkerboard 
assay, combining GF and TF results in additive effect and 
has impressive efficacy to several clinical dermatophytes 
FIGURE 1 - Hyphal damage expressed in percentage of the griseofulvin (GF) () and terbinafine (TF) ()  alone and in combination 
(). A) Hyphal damage of the TME 16 drug resistant isolate to the combination of TF and GF antifungals at concentrations below 
MIC; B) Hyphal damage of TME 32 drug sensitive isolate to combination of TF and GF antifungals at concentrations below MIC. 
Different letters above the hyphal damage represent a statistically significant difference (p <0.05).
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including two hard to kill multidrug-resistant fungi 
isolates. This enhanced activity might be due to having 
selected drugs of different mechanisms of actions: 
inhibition of mitosis (GF) and ergosterol depletion (TF), 
as it is believed that TF might be altering the membrane 
by blocking the squalene epoxidase which ultimately 
facilitates cellular internalization of GF allowing for re-
sensitizing via DNA damage of the multidrug-resistant 
isolates. 
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